Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

    Results: 1 to 20 of 102

    1.

    Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

    Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE.

    Am J Prev Med. 2009 Apr;36(4):341-50. doi: 10.1016/j.amepre.2008.11.020.

    PMID:
    19285199
    [PubMed - indexed for MEDLINE]
    2.

    Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.

    Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G; Adipogenic and Metabolic Effects of APDs Conference Speakers, Allison DB.

    Front Psychiatry. 2012;3:62. doi: 10.3389/fpsyt.2012.00062. Epub 2012 Jun 28.

    PMID:
    22754543
    [PubMed]
    Free PMC Article
    3.

    Monitoring and managing weight gain in the mentally ill.

    Ganguli R, Vreeland B, Newcomer JW.

    J Clin Psychiatry. 2007 Jun;68(6):e14. Review. No abstract available.

    PMID:
    17592901
    [PubMed - indexed for MEDLINE]
    4.

    Best practices: implementation of a glucose screening program based on diffusion of innovation theory methods.

    Nicol GE, Morrato EH, Johnson MC, Campagna E, Yingling MD, Pham V, Newcomer JW.

    Psychiatr Serv. 2011 Jan;62(1):12-4. doi: 10.1176/appi.ps.62.1.12.

    PMID:
    21209293
    [PubMed - indexed for MEDLINE]
    5.

    Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.

    Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ, Maeda J, Yingling M, Newcomer JW.

    Neuropsychopharmacology. 2007 Dec;32(12):2561-9. Epub 2007 Mar 21.

    PMID:
    17375138
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

    Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW.

    Am J Psychiatry. 2009 Mar;166(3):345-53. doi: 10.1176/appi.ajp.2008.08030383. Epub 2009 Jan 15.

    PMID:
    19147694
    [PubMed - indexed for MEDLINE]
    7.

    Risperidone-associated diabetic ketoacidosis.

    Haupt DW, Newcomer JW.

    Psychosomatics. 2001 May-Jun;42(3):279-80. No abstract available.

    PMID:
    11351122
    [PubMed - indexed for MEDLINE]
    8.

    Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.

    Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE.

    Neuropsychopharmacology. 2008 Apr;33(5):985-94. Epub 2007 Jul 18.

    PMID:
    17637612
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Metabolic screening in children receiving antipsychotic drug treatment.

    Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

    Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

    PMID:
    20368487
    [PubMed - indexed for MEDLINE]
    10.

    Challenges and solutions to integrating mental and physical health care.

    Druss BG, Newcomer JW.

    J Clin Psychiatry. 2007 Apr;68(4):e09. Review.

    PMID:
    17474799
    [PubMed - indexed for MEDLINE]
    11.

    Comparing safety and tolerability of antipsychotic treatment.

    Newcomer JW, Lieberman JA.

    J Clin Psychiatry. 2007 Mar;68(3):e07. Review.

    PMID:
    17388701
    [PubMed - indexed for MEDLINE]
    12.

    Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.

    Morrato EH, Newcomer JW, Allen RR, Valuck RJ.

    J Clin Psychiatry. 2008 Feb;69(2):316-22.

    PMID:
    18251625
    [PubMed - indexed for MEDLINE]
    13.

    Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.

    Morrato EH, Druss BG, Hartung DM, Valuck RJ, Thomas D, Allen R, Campagna E, Newcomer JW.

    Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):66-75. doi: 10.1002/pds.2062. Epub 2010 Nov 15.

    PMID:
    21182154
    [PubMed - indexed for MEDLINE]
    14.

    Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

    Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

    Diabetes Care. 2009 Jun;32(6):1037-42. doi: 10.2337/dc08-1720. Epub 2009 Feb 24.

    PMID:
    19244091
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

    Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

    Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

    PMID:
    20048219
    [PubMed - indexed for MEDLINE]
    16.

    The metabolic effects of antipsychotic medications.

    Newcomer JW, Haupt DW.

    Can J Psychiatry. 2006 Jul;51(8):480-91. Review.

    PMID:
    16933585
    [PubMed - indexed for MEDLINE]
    17.

    Chronic corticosterone treatment impairs spontaneous alternation behavior in rats.

    Bardgett ME, Taylor GT, Csernansky JG, Newcomer JW, Nock B.

    Behav Neural Biol. 1994 Mar;61(2):186-90.

    PMID:
    8204085
    [PubMed - indexed for MEDLINE]
    18.

    Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.

    Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO.

    Psychopharmacology (Berl). 1994 Nov;116(3):291-6.

    PMID:
    7534423
    [PubMed - indexed for MEDLINE]
    19.

    A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.

    Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S.

    J Clin Psychopharmacol. 2010 Aug;30(4):425-30. doi: 10.1097/JCP.0b013e3181e69042. Erratum in: J Clin Psychopharmacol. 2010 Oct;30(5):652.

    PMID:
    20571437
    [PubMed - indexed for MEDLINE]
    20.

    Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis.

    Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW Jr.

    Arch Gen Psychiatry. 2000 Dec;57(12):1165-73.

    PMID:
    11115331
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Search details

      See more...

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk